(Q33397092)

26 July 2017

title

Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents (English)

1 reference

26 July 2017

1 reference

Sif Gudbrandsdottir

7

0 references

Leonardo Boiocchi

object named as

Leonardo Boiocchi

4

0 references

Hans K. Hasselbalch

object named as

Hans Carl Hasselbalch

3

0 references

James Bruce Bussel

9

object named as

James B Bussel

1 reference

26 July 2017

1

Waleed Ghanima

1 reference

26 July 2017

Peter Junker

2

1 reference

26 July 2017

Julia T Geyer

5

1 reference

26 July 2017

Xingmin Feng

6

1 reference

26 July 2017

Attilio Orazi

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

9 September 2011

1 reference

British Journal of Haematology

26 July 2017

published in

1 reference

26 July 2017

volume

155

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

248-255

1 reference

Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Pathogenesis of chronic immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Bone marrow reticulin and collagen content in patients with adult chronic immune thrombocytopenic purpura: a Danish nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Hepatocyte growth factor accelerates thrombopoiesis in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Biology and chemistry of thrombopoietic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Romiplostim or standard of care in patients with immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08845.X

10.1111/J.1365-2141.2011.08845.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference